CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Hirsh J, Dalen J, Anderson DR et al.: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest119(Suppl. 1) S8–S21 (2001).
  Medline CASGoogle Scholar
• 2  Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood106,2329–2333 (2005).
  Medline CASGoogle Scholar
• 3  Sconce EA, Kamali F: Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. Eur. J. Haematol.77(6),457–462 (2006).▪ One of the first papers to report genotype-based algorithms to calculate warfarin dose.
  Medline CASGoogle Scholar
• 4  Aquilante CL, Langaee TY, Lopez LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther.79(4),291–302 (2006).
  Medline CASGoogle Scholar
• 5  Yin T, Miyata T: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 – rationale and perspectives. Thromb. Res.120(1),1–10 (2007).
  Medline CASGoogle Scholar
• 6  van Aken J, Schmedders M, Feuerstein G, Kollek R: Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am. J. Pharmacogenomics3(3),149–155 (2003).
  Medline CASGoogle Scholar
• 7  Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med.352,2285–2293 (2005).▪ First paper to describe the correlation of VKORC1 with warfarin dosing.
  Medline CASGoogle Scholar
• 8  Veenstra DL, You JH, Rieder MJ et al.: Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics15,687–691 (2005).
  Medline CASGoogle Scholar
• 9  Wadelius M, Chen LY, Downes K et al.: Common VKORC1 and GGCXpolymorphisms associated with warfarin dose. Pharmacogenomics J.5,262–270 (2005).
  Medline CASGoogle Scholar
• 10  D’Andrea G, D’Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood105,645–649 (2005).
  MedlineGoogle Scholar
• 11  Vecsler M, Loebstein R, Almog S et al.: Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin. Thromb. Haemost.95,205–111 (2006).
  Medline CASGoogle Scholar
• 12  Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G: Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics8(11),1545–1550 (2007).▪ A previous paper in the same central Italian population describing a multiple linear regression model including VKORC1 and CYP2C9.
  CASGoogle Scholar
• 13  Wu AH, Wang P, Smith A et al.: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics9(2),169–178 (2008).
  CASGoogle Scholar
• 14  Schwarz UI, Ritchie MD, Bradford Y et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med.358(10),999–1008 (2008).
  Medline CASGoogle Scholar
• 15  Flockhart DA, O’Kane D, Williams MS et al.: Testing of CYP2C9, VKORC1 alleles for warfarin use pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet. Med.10(2),139–150 (2008).
  Medline CASGoogle Scholar
• 16  Carlquist JF, Horne BD, Muhlestein JB et al.: Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis22(3),191–197 (2006).
  Medline CASGoogle Scholar
• 17  Geisen C, Watzka M, Sittinger K et al: VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost.94(4),773–779 (2005).
  MedlineGoogle Scholar
• 18  Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivity. Hum. Mol. Genet.14,1745–1751 (2005).
  Medline CASGoogle Scholar
• 19  Caldwell MD, Awad T, Johnson JA et al.: CYP4F2 genetic variant alters required warfarin dose. Blood111(8),4106–4112 (2008).▪▪ First paper to describe the contribution of CYP4F2 genetic variant rs2108622 to the warfarin dosing.
  Medline CASGoogle Scholar
• 20  Cooper GM, Johnson JA, Langaee TY et al.: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood112(4),1022–1027 (2008).
  Medline CASGoogle Scholar
• 21  Novelli G, Ciccacci C, Borgiani P, Papaluca-Amati M, Abadie E: Genetic tests and genomic biomarkers: regulation, qualification and validation. Clinical Cases in Mineral and Bone Metabolism5(2),149–154 (2008).
  Google Scholar
• 101  US FDA News www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html
  Google Scholar